ADMA Biologics Inc (ADMA) Q3 2024 Earnings Call Highlights: Record Revenue and Net Income Surge

GuruFocus.com2024-11-08

Total Revenue: $119.8 million, a 78% increase year-over-year. Adjusted EBITDA: $45.4 million, a growth rate of 256% from the previous year. Net Income: $35.9 million, a 1,300% increase year-over-year....

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2481815142?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/sAJi76aiBSVt7EuaxIOfdQ--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/e73e3b670441ba3be0e1723be76b8008","is_english":true,"pubTime":"2024-11-08 15:28","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2481815142","market":"us","top_or_hot":-1,"title":"ADMA Biologics Inc (ADMA) Q3 2024 Earnings Call Highlights: Record Revenue and Net Income Surge","media":"GuruFocus.com","content":"<div>\n<p>Total Revenue: $119.8 million, a 78% increase year-over-year.\nAdjusted EBITDA: $45.4 million, a growth rate of 256% from the previous year.\nNet Income: $35.9 million, a 1,300% increase year-over-year....</p>\n\n<a href=\"https://finance.yahoo.com/news/adma-biologics-inc-adma-q3-072801718.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ADMA Biologics Inc (ADMA) Q3 2024 Earnings Call Highlights: Record Revenue and Net Income Surge</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nADMA Biologics Inc (ADMA) Q3 2024 Earnings Call Highlights: Record Revenue and Net Income Surge\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-08 15:28 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/adma-biologics-inc-adma-q3-072801718.html><strong>GuruFocus.com</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Total Revenue: $119.8 million, a 78% increase year-over-year.\nAdjusted EBITDA: $45.4 million, a growth rate of 256% from the previous year.\nNet Income: $35.9 million, a 1,300% increase year-over-year....</p>\n\n<a href=\"https://finance.yahoo.com/news/adma-biologics-inc-adma-q3-072801718.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ADMA","symbol_name":"ADMA Biologics Inc","start_time":0,"source_url":"https://finance.yahoo.com/news/adma-biologics-inc-adma-q3-072801718.html","article_id":"2481815142","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/sAJi76aiBSVt7EuaxIOfdQ--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/e73e3b670441ba3be0e1723be76b8008"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2481815142","pubTimestamp":1731050881,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Total Revenue: $119.8 million, a 78% increase year-over-year.Adjusted EBITDA: $45.4 million, a growth rate of 256% from the previous year.Net Income: $35.9 million, a 1,300% increase year-over-year.Gross Margin: 50% for the third quarter of 2024, compared to 37% in the third quarter of 2023.Operating Cash Flow: $25 million generated during the third quarter.Net Leverage Ratio: Improved to approximately 0.1x, annualizing the third quarter results.GuruFocus has detected 6 Warning Sign with ADMA.For the complete transcript of the earnings call, please refer to the full earnings call transcript.ADMA Biologics Inc  raised its financial guidance for 2024 and 2025, expecting total revenues to exceed $415 million and $465 million, respectively.The company faces challenges in securing enough high titer plasma to meet the growing demand for ASCENIV.Q: Can you provide more details on the potential for ASCENIV to become a $1 billion revenue opportunity and the efforts to increase hyperimmune plasm","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"ADMA":"ADMA Biologics Inc"},"translate_title":"ADMA Biologics Inc(ADMA)2024年第三季度收益看涨期权亮点：创纪录的收入和净利润激增","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ADMA":1},"content_text":"Total Revenue: $119.8 million, a 78% increase year-over-year.\nAdjusted EBITDA: $45.4 million, a growth rate of 256% from the previous year.\nNet Income: $35.9 million, a 1,300% increase year-over-year.\nGross Margin: 50% for the third quarter of 2024, compared to 37% in the third quarter of 2023.\nOperating Cash Flow: $25 million generated during the third quarter.\nNet Leverage Ratio: Improved to approximately 0.1x, annualizing the third quarter results.\n\n\nWarning! GuruFocus has detected 6 Warning Sign with ADMA.\n\nRelease Date: November 07, 2024\nFor the complete transcript of the earnings call, please refer to the full earnings call transcript.\n Positive Points \n\nADMA Biologics Inc (NASDAQ:ADMA) reported a significant increase in total revenues, reaching $119.8 million, a 78% year-over-year growth.\nThe company achieved a remarkable 256% growth in adjusted EBITDA, reaching $45.4 million.\nNet income saw an impressive increase of 1,300% year-over-year, amounting to $35.9 million.\nADMA Biologics Inc (NASDAQ:ADMA) raised its financial guidance for 2024 and 2025, expecting total revenues to exceed $415 million and $465 million, respectively.\nThe company is optimistic about ASCENIV's potential as a billion-dollar revenue opportunity, with strategic production adjustments to meet growing demand.\n\n Negative Points \n\nCorporate gross margins were impacted by a low-margin spot sale of normal source plasma, which affected the overall margin performance.\nThe company faces challenges in securing enough high titer plasma to meet the growing demand for ASCENIV.\nThere is uncertainty regarding the timeline for the yield enhancement production project and its impact on future revenues.\nADMA Biologics Inc (NASDAQ:ADMA) discontinued the production of 1 ml NABI-HB due to unfavorable margins, which may affect short-term revenue.\nThe company is reliant on third-party plasma collectors, which could pose risks to plasma supply stability and cost management.\n\n Q & A Highlights \nQ: Can you provide more details on the potential for ASCENIV to become a $1 billion revenue opportunity and the efforts to increase hyperimmune plasma supply? A: Adam Grossman, President and CEO, explained that the company is optimistic about ASCENIV's growth potential, driven by strong demand indicators and strategic initiatives like the VIP donor program and ADMAlytics. These efforts aim to optimize plasma collections and retain high-titer plasma donors, which are crucial for ASCENIV's production. The company is also negotiating with third-party collectors to expand plasma supply. While the exact timeline for reaching $1 billion in revenue is uncertain, the company is focused on accelerating growth and expects significant margin expansion from yield enhancements starting in 2026.\nQ: Is churn a significant issue with plasma donors, and do you have enough safety stock to meet long-term contracts? A: Adam Grossman acknowledged that donor churn is a natural occurrence, but the company is actively working to retain high-titer donors. While they don't have all the safety stock needed, they have sufficient plasma inventory to continue production and drive revenue growth. The company is optimistic about securing additional plasma supply through ongoing negotiations with third-party collectors.\nQ: How does the change in administration and potential FDA personnel changes impact ADMA and the plasma industry? A: Adam Grossman expressed confidence that the change in administration would not negatively impact ADMA or the plasma industry. He highlighted bipartisan support for plasma-derived therapies and ADMA's unique position as a U.S.-based manufacturer. The company is well-positioned to benefit from any potential legislation favoring domestic production.\nQ: Do you need more plasma donor facilities to reach the $1 billion target, and is there a risk in sharing high RSV titer screening methods with third parties? A: Adam Grossman stated that the current 10 facilities are sufficient, and there are no plans to expand. The company controls the screening process and does not share proprietary methods with third parties. Third-party collectors only know which donors to collect from, ensuring ADMA retains control over the science and testing.\nQ: Why didn't you raise full-year guidance more, and is the yield enhancement benefit included in 2025 guidance? A: Adam Grossman explained that the guidance remains conservative, and the yield enhancement benefit is not yet included in 2025 projections. The company had a one-time plasma sale in the quarter, which won't recur, and they have stopped producing a low-margin product. Despite these factors, they expect continued revenue growth and margin expansion, particularly with yield enhancements in 2026.\nFor the complete transcript of the earnings call, please refer to the full earnings call transcript.This article first appeared on \nGuruFocus.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.30.2","shortVersion":"4.30.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2481815142"}